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Abstract
Introduction—Pan American Health Organization’s (PAHO) ProVac Initiative aims to 
strengthen countries’ technical capacity to make evidence-based immunization policy. With 
financial support from the Bill and Melinda Gates Foundation, PAHO established the ProVac 
International Working Group (IWG), a platform created for two years to transfer the ProVac 
Initiative’s tools and methods to support decisions in non-PAHO regions.
Methods—In 2011, WHO Regional Offices and partner agencies established the IWG to transfer 
the ProVac framework for new vaccine decision support, including tools and trainings to other 
regions of the world. During the two year period, PAHO served as the coordinating secretariat and 
partner agencies played implementing or advisory roles.
Results—Fifty nine national professionals from 17 countries received training on the use of 
economic evaluations to aid vaccine policy making through regional workshops. The IWG 
provided direct technical support to nine countries to develop cost-effectiveness analyses to 
inform decisions. All nine countries introduced the new vaccine evaluated or their NITAGs have 
made a recommendation to the Ministry of Health to introduce the new vaccine.
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Discussion—Developing countries around the world are increasingly interested in weighing the 
potential health impact due to new vaccine introduction against the investments required. During 
the two years, the ProVac approach proved valuable and timely to aid the national decision 
making processes, even despite the different challenges and idiosyncrasies encountered in each 
region. The results of this work suggest that: (1) there is great need and demand for technical 
support and for capacity building around economic evaluations; and (2) the ProVac method of 
supporting country-owned analyses is as effective in other regions as it has been in the PAHO 
region.
Conclusion—Decision support for new vaccine introduction in low- and middle-income 
countries is critical to guiding the efficient use of resources and prioritizing high impact 
vaccination programs.
Keywords
Immunization program; Economic evaluations; Cost-effectiveness analysis; Evidence-based 
policy; Immunization policy
1. Introduction
According to a study on the global burden of childhood pneumonia and diarrhea, estimates 
of annual childhood mortality due to rotavirus-associated diarrhea are 192,000 globally, and 
another 411,000 children younger than 5 die each year from pneumococcal disease [1]. 
Additionally, 266,000 women died prematurely in 2012 from cervical cancer caused by 
human papillomavirus (HPV) [2]. Vaccines to prevent these priority diseases offer 
opportunities to make substantial gains in health, oftentimes at a relatively lower cost than 
other preventive strategies. However, the relative value of many new vaccines may depend 
on variables that vary greatly between and within countries; consequently, policy decisions 
to introduce new vaccines require an evidence base that reflects national conditions.
Using the Pan American Health Organization (PAHO) ProVac Initiative’s framework for 
promoting evidence-based decision-making, the International Working Group (IWG) was 
created in 2011 to help strengthen national capacity for evidence-based decisions regarding 
the introduction of new vaccines in developing countries in regions other than Latin 
America and the Caribbean (LAC). This article is an introductory overview of the work 
conducted by the IWG. More details about this work will be covered in other publications 
within this special Vaccine supplement.
2. Background
In 2004, PAHO created the ProVac Initiative. Since then, the ProVac Initiative has trained 
high-level technical staff from ministries of health from over 25 countries in the Latin 
America and Caribbean (LAC) region on the use of economic evaluations in the decision-
making process for introducing new and underutilized vaccines to prevent rotavirus 
diarrhea, pneumococcal disease, and human papilloma virus (HPV) infection. ProVac has 
also supported 21 country-owned cost-effectiveness analyses on rotavirus, pneumococcal 
conjugate, and HPV vaccines to inform national decision-making processes in LAC.
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Implementing the ProVac Initiative in the Americas has yielded a number of valuable 
lessons and tools for supporting countries in making evidence-based decisions around the 
introduction of new vaccines. Specifically, multidisciplinary country study teams that collect 
data and do analysis have used TRIVAC (the integrated childhood vaccination cost-
effectiveness model for rotavirus, pneumococcal conjugate, and Haemophilus influenzae 
type b [Hib] vaccines) to ensure that immunization policymakers in LAC recognize study 
results and weigh their outcomes in decisions about whether to introduce a new vaccine [3].
Over the years, PAHO has received requests from technical cooperation organizations and 
countries outside of the LAC region to implement ProVac tools and methods. Under the 
umbrella of the ProVac IWG, PAHO worked closely with organizations involved with 
global immunization activities – Agence de Médecine Préventive (AMP), United States’ 
Centers for Disease Control and Prevention (CDC), Program for Appropriate Technology in 
Health (PATH), the Sabin Vaccine Institute, and WHO headquarters, regional and country 
offices – to leverage lessons learned in the Americas for use in other regions.
It was decided to form the ProVac IWG to serve as the mechanism to bring together the 
above organizations because IWG would:
• Provide a unique platform to channel requests for technical assistance from 
developing countries around economic analysis for new vaccines and for 
adjustments/updates to existing ProVac tools and methodologies.
• Improve coordination among relevant parties supporting evidence-based decisions 
about introducing vaccines in developing countries—which in turn clarifies roles, 
responsibilities, and collaborations that help to avoid overlap and maximizes 
efforts.
• Increase the flexibility of the ProVac tools and methods, helping to ensure their 
appropriate use in different epidemiological and geographical contexts.
• Generate and encourage the publication of evidence to promote greater consistency 
between regions, both in the use of standardized methods and tools, and in the 
country-led evidence-based approach, too.
3. Methods
In 2011, WHO regional offices and partner agencies met at PAHO headquarters to establish 
the ProVac IWG, as a platform to transfer ProVac’s framework and experience (including 
its tools, methods, and training exercises that support making evidence-based decisions 
about introducing new vaccines) in selected countries in Africa, the Eastern Mediterranean 
and Europe—regions where IWG partners have strong existing networks. In 2012, IWG 
received support from the Bill and Melinda Gates Foundation for two years, during which 
the technical cooperation focused on low- and middle-income countries. These are regions 
where the burden of rotavirus, pneumococcal and cervical cancer is greatest and where 
countries are challenged by limited capacity to build evidence bases to support the decision-
making process for introduction of new vaccines. The work focused on support to countries 
facing decisions about introduction of pneumococcal conjugate vaccine and/or rotavirus 
vaccine using the TRIVAC impact and cost-effectiveness model.
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During the two years, PAHO served as coordinating secretariat, and partner agencies played 
implementing or advisory roles. AMP provided direct technical support to selected countries 
in the Eastern Mediterranean (EMR) and Europe (EUR); PATH did the same in Africa 
(AFR). Both partner agencies received training from PAHO as well as subsequent support 
from the WHO headquarters and regional offices. Sabin Vaccine Institute supported AMP’s 
and PATH’s capacity-building activities at country level with their expertise in effectively 
communicating evidence for informed decision-making; the CDC provided advisory support 
on epidemiological data quality. The IWG leveraged existing country relationships and 
subject matter expertise to support the rollout of this framework in nine countries. The 
countries were selected according to the following criteria: (1) interest from the ministry of 
health or an official request to conduct an economic evaluation, (2) a pending decision 
regarding a new vaccine introduction, and (3) a partner presence in the country.
The ProVac IWG had three main objectives: (1) transferring tools, methods, and lessons 
learned in the Americas to other regions to support national decisions about new vaccine 
introduction, (2) building national capacity for using economic analyses in low- and middle-
income countries around the world, and (3) providing direct technical support collecting data 
and conducting economic analyses to inform immunization policy in low- and middle-
income countries. Details and follow-up on the objectives are elaborated below.
Considering differences in data availability, data quality, and new vaccine policy questions 
that exist between WHO regions, the ProVac IWG collaborated to adapt the tools used in the 
Americas for use to support national-level decision-making about the introduction of new 
vaccines in developing countries in the WHO Regions of AFR, EMR and EUR. This 
included revising input parameters of the model (as needed) and translating the ProVac tools 
and methods to French and Russian. A number of improvements to TRIVAC were also 
made as a result of direct feedback from countries involved in the IWG. These include: (1) 
greater clarity in the way inputs were organized —e.g., dose-specific vaccine efficacy and 
assumptions about vaccine timeliness (on-time, delayed) and age restrictions (age-restricted 
or unrestricted); (2) improved popup explanations and workshop materials designed to suit a 
wider geographical audience; (3) improved graphical output; (4) greater flexibility to 
customize the type of diseases considered by the country team—e.g., pneumonia 
admissions, X-ray-confirmed pneumonia, or clinical pneumonia, etc.; (5) development of 
features to help users calculate a plausible case fatality ratio and understand how it was 
derived—i.e., combining a top-down (proportional mortality) estimate of deaths with a 
bottom-up (incidence-based) estimate of cases; (6) increased scope of the OLIVES on-line 
data repository—e.g., incorporating evidence from outside the Americas on vaccine type 
coverage, waning vaccine protection etc.; and (7) the addition of two new language options 
for users of the model—i.e., Russian and French.
National capacity to perform economic analyses to inform new vaccine introduction is 
considered limited in most developing countries. To address this challenge and ensure that 
the IWG’s tools helped a greater number of public health decision-makers, IWG partners 
organized regional workshops to provide training on basic concepts of health economics and 
disease epidemiology, and on the use of ProVac tools for economic analyses. Regional 
workshops provided national public health professionals with a broad understanding of how 
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to collect and critically assess data, conduct analyses, interpret results, and contextualize 
findings in light of other relevant criteria for deciding on whether to introduce a new 
vaccine.
ProVac IWG partner-led regional workshops used PAHO’s TRIVAC model as a practical 
training tool. TRIVAC is an Excel-based, cohort model that provides users with a friendly, 
stepwise template to collect data for each model parameter [3]. It evaluates the incremental 
program costs, health benefits gained, and disease-associated costs averted from introducing 
vaccines that prevent Hib, rotavirus, and pneumococcal infection.
Although the regional workshops were the primary method for training national people on 
using ProVac tools, the ProVac Centers of Excellence also developed training materials on 
health economics and evidence-based decision-making in the Latin American region [4]. 
The training materials, which explained the key concepts required for understanding the 
tools and how to use them, were provided to country teams and discussed in regional 
workshops.
The ProVac Initiative promotes capacity-building as an overarching principle to ensure 
long-term sustainable impact. As stated above, the IWG supported this concept by helping to 
form multidisciplinary country teams to use ProVac tools, carry out data collection, conduct 
analysis, and communicate study results to policymakers. The majority of these study teams 
were appointed by the Ministry of Health; they included participation from WHO regional 
and/or country immunization staff, Expanded Programme on Immunization (EPI) managers, 
and relevant experts from ministries of health and academic centers (health economists, 
epidemiologists, pediatricians, public health and immunization experts). In each country, a 
ministry of health focal point or a national consultant was also identified to coordinate the 
study activities. These teams served as technical working groups to support deliberations on 
the introduction of new vaccines by National Immunization Technical Advisory Groups 
(NITAGs), where these exist. IWG partners provided ongoing technical support throughout 
the study, with in-country visits to initiate and support the study and a final visit to review 
databases, address any methodological challenges, and assist in interpreting the results for 
decision-making purposes.
CDC partners led technical reviews and provided recommendations regarding 
epidemiological data on rotavirus and pneumococcal disease. After data collection, 
multidisciplinary country teams critically assessed the data and conducted the analyses. 
With support from the whole ProVac IWG, AMP led studies in EMR and in EUR. Similarly, 
PATH led studies in AFR, complementing work previously conducted in other African 
countries. The current supplement showcases a more detailed description of AMP’s 
experience, as well as country-led publications from the three regions studied [5–12].
In most cases, the evidence is only as good as the methods used to communicate. The Sabin 
Vaccine Institute led an effort to develop a communication and advocacy strategy to be 
applied in study countries to ensure that the evidence generated through ProVac studies 
reaches stakeholders and decision-makers. The institute developed a practical guide and 
several templates to help multidisciplinary national teams to package their evidence into 
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concise and practical materials so that the evidence relevant to the decision process could be 
effectively communicated to a range of stakeholders. The strategy involved these steps:
• Analyze the country’s existing decision-making process for introducing new 
vaccines.
• Identify stakeholders and their roles in the decision process.
• Identify relevant evidence that should be used to properly inform the decision.
• Address common questions about cost-effectiveness and its role in the decision-
making on new vaccine introduction.
• Create concise and effective technical presentations based on data from the 
economic analysis performed.
• Construct key messages and provide supporting evidence to accompany the results 
of the economic analyses.
• Draft policy briefs that include the national economic analysis and other relevant 
criteria for decision-making.
• Draft technical reports, including more detailed information about the economic 
evaluation that was conducted.
4. Results
Economic analyses represent one component of a broader policy framework for evidence-
based decisions regarding the introduction of new vaccines. PAHO’s ProVac introduction 
policy framework [13], which considers technical, programmatic, and social criteria, has 
helped guide countries to use economic analyses in the context of other relevant decision 
criteria to ensure that a comprehensive policy analysis is conducted to ground decisions in 
evidence. The ProVac IWG promoted the use of the same framework.
ProVac IWG held both an initial and final meeting during the 2-year period. The initial 
meeting served as a platform for the IWG partners to agree on specific activities and for 
PAHO to train implementing partners on the TRIVAC model and ProVac methods; the final 
meeting was to evaluate the IWG’s outcomes. This allowed the incorporation of 
improvements in the TRIVAC model to accommodate the needs of countries outside the 
LAC region. Those improvements included adding two new language options (French and 
Russian), a designated area for manual calculations, and updated default data.
A total of 59 national professionals from 17 countries received training through IWG’s 
regional workshops. Each partner had existing regional ties in one or more of these regions 
and the workshops complemented their ongoing regional work.
AMP led regional workshops on the use of economic analyses to inform decisions around 
the introduction of pneumococcal conjugate vaccines in EUR and EMR in 2012 and 2013 
respectively; WHO headquarters, regional, and country offices provided support. Similarly, 
PATH led a workshop on conducting cost-effectiveness analyses of new vaccine 
introductions, focused on the rotavirus vaccine in AFR in 2013. This workshop in AFR 
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complemented two previous workshops PATH had organized on the use of economic 
analyses in 2011 (funded by other sources). The regional workshops targeted EPI managers, 
national health economists, and other relevant ministry of health professionals working in 
the area of vaccine-preventable diseases. During the workshops, country teams that were 
conducting their own cost-effectiveness studies within the ProVac IWG shared their 
experiences; this helped achieve the ProVac objective of capacity-building.
The IWG provided direct technical support to nine countries1 to develop cost-effectiveness 
analyses and inform decisions on pneumococcal conjugate or rotavirus vaccines [see Table 
1]. Seven of those nine countries had received training as part of the above-mentioned 
regional workshops. After considering the cost-effectiveness results obtained and taking into 
account other criteria considered relevant, countries either made the decision whether or not 
to introduce the new vaccine that had been evaluated, or the countries’ NITAGs or 
equivalent advisory bodies used the new evidence and made recommendations to their 
respective ministries of health [see Table 2 for country-specific information.]
Where data gaps or weaknesses were identified from national sources, the national team 
presented recommendations to their authorities to strengthen surveillance and health 
information systems (HIS).
The resources needed for supporting EUR consisted of the partner’s staff time and travel 
costs, workshop participants’ travel and per diems, and translation of materials into French 
and Russian. In EMR and AFR, in addition to all these expenses, a small amount of funds 
was also required to convene internal working group meetings within each of the countries, 
to cover coffee breaks, and as a financial incentive for nationals to attend the meeting 
(which was not necessary in EUR). Lessons learned in the EUR and EMR regions include 
(1) the need for a well-balanced multidisciplinary team in the country to carry out the cost-
effectiveness analysis (CEA), including all relevant specialties and institutions, (2) the 
importance of involving all stakeholders from the start of the study so that study results are 
accepted by all parties, and (3) the necessity of providing a regional approach which 
encourages peer-to-peer interactions between countries that builds esprit de corps among 
investigators and embraces intellectual development.
Partners working in the AFR region faced different challenges including a more complex 
country selection process. They also learned that having a country office where the study is 
being conducted and holding regional workshops before beginning country analyses are 
critical elements for success of the work. A specific lesson learned from AFR was the 
importance of beginning these studies well in advance of policymaking timelines that are 
advanced by the Global Alliance for Vaccines and Immunization (Gavi).
5. Discussion
Many of the countries supported through the ProVac IWG are moving away from donor-
funded immunization programs. As such, they have an increasing interest in weighing value 
against the financial cost of adopting the new vaccine. The ProVac approach to conducting 
1The nine countries were: Albania, Azerbaijan, Croatia, Egypt, Georgia, Iran, Kenya, Senegal, and Uganda.
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country-owned economic evaluations can be a valuable and timely aid to this national 
decision-making process, although the unique challenges encountered in each region require 
further consideration. For Gavi-eligible countries, conducting a country-level CEA is not a 
current prerequisite for funding and so the dynamics and motivations vary. A cost concern 
with regard to a new vaccine’s affordability is more pertinent. Despite this, we consider the 
process of generating and collecting data required for a cost-effectiveness study relevant to 
Gavi-eligible countries: It promotes a culture for evidence-based decision-making while also 
helping the government evaluate the long-term strategic planning and sustainability of the 
new vaccine being considered for introduction.
Similar to ProVac’s experience in the Americas, one of the key problems we faced in these 
countries was lack of national-level data on important information such as disease burden 
and serotype distribution. This often led to using regional data or international estimates for 
these parameters. One lesson learned is that countries prefer national data, but this requires 
they anticipate this and that they have surveillance systems in place well before the analysis 
is conducted, or that they perform focused studies that provide reliable, quality national data. 
When this has not happened, the question of what constitutes a good surrogate often arises. 
Examples include regional estimates and data from bordering countries. The variable 
national technical expertise on subject matter and on how to set up these studies is another 
lesson to highlight, and indicates the need for regional WHO offices and other partners help 
them build such capacity.
Sustainability or “nationalization” of the process is yet to be documented in these regions. 
The Americas has had several experiences of countries performing further studies with 
significantly less support from the ProVac team [14], but this is yet to happen in the IWG 
regions where the ProVac support is more recent.
As will be further reinforced in the specific related publications in this supplement, the 
experience suggested that (1) there is great need and demand for technical support and for 
capacity-building to conduct economic evaluations at the national level in the regions where 
the work took place, and (2) the ProVac method of supporting country-owned analyses 
through extensive training, direct support, and promotion of country ownership of process 
and results could become as effective in other regions as it has been in the PAHO region if it 
is properly adapted to the regional context. This collaboration is one of several experiences 
where regions with more advanced immunization programs transfer successful initiatives to 
other regions. More international and regional funding mechanisms for cross-regional 
sharing are needed to maximize the impact of existing initiatives and prevent having each 
region “reinvent the wheel.”
The leveraging of expertise of the partner agencies proved useful. The PAHO ProVac team, 
which includes the modeling team at the London School of Hygiene and Tropical Medicine 
(LSHTM) and a core team of international consultants, provided its years of experience 
developing tools and trainings specifically for country teams and supporting country-led 
economic analysis, and provided a coordinating role for the group. PATH offered a strong 
health economics expert team, and also had disease epidemiology experts available to 
provide support. AMP provided effective training techniques. CDC provided important 
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subject matter expertise on epidemiological and surveillance data. WHO headquarters and 
regional offices provided convening power and global immunization policy expertise. The 
Sabin Vaccine Institute offered useful and practical tools for communicating results to 
national authorities.
This experience demonstrated again the critical importance of establishing national 
multidisciplinary teams for the country to gain ownership over the process and its results. 
User-friendly, scientifically robust decision-support tools are needed in resource-constrained 
and/or data-sparse settings and the ProVac tools are an option for filling this gap. The IWG 
work also confirmed that having a focal point from within the ministry of health or other 
national institution who is assigned to lead and coordinate the study, rather than hiring an 
external consultant, is likely more sustainable in the long term and more effective in 
national-capacity development. However, this could prove challenging, given the more 
limited time that ministries of health and sometimes even WHO regional or country office 
staff have to provide support—especially in high-risk regions overwhelmed with emergency 
or dire health situations as well as with international technical cooperation activities such as 
in AFR. In the future, it will be necessary to find a more systematized way to deal with 
country demand for technical cooperation and to prioritize the countries. Finally, as shown 
in Table 2, technical support to strengthen capacity on economic evaluations of vaccines can 
be resource-intensive. Combining innovative ways of interacting with local technicians and 
decision-makers through distance learning with high-quality, easy-to-use tools is necessary 
for a sustainable approach going forward.
6. Conclusion
A nationally based, evidence-driven decision process for new vaccine introduction in low- 
and middle-income countries is critical to guiding the efficient use of resources and 
prioritizing high-impact vaccination programs. It is the antithesis of the top-down approach. 
This experience demonstrated that the ProVac method for capacity-building – which 
includes using workshops to promote the socialization of general concepts and tools, 
providing direct support to countries after an official ministry of health request has been 
received, convening a multidisciplinary team, and fostering strong working relationships 
between NITAG, ministry authorities, and the team conducting the analysis – can be 
implemented successfully in countries outside of the LAC region.
The ProVac method provides an opportunity to get multiple national stakeholders to sit at 
the same table, which enhances the evidence-based decision-making process at country 
level. Several agencies are well-suited to provide this technical assistance and coordination 
at the global level will be required. ProVac IWG partners have expressed their interest in 
continuing to collaborate on this important work. Going forward, both PAHO and WHO 
may have an opportunity to coordinate the expanded reach of the ProVac toolkit and 
decision-support methods to additional regions and countries requiring real-time support.
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Table 1
Countries and people trained through workshops and through direct technical support.
EUR region EMR region AFR Region
Countries trained
 through workshops
Albania
Croatia
Estonia
Georgia
Egypt
Islamic
Republic of Iran
Iraq
Jordan
Lebanon
Tunisia
Botswana
Kenya
Nigeria
Senegal
South Africa
Uganda
Number of national
 people trained
 through workshops
18 20 20
Countries that received
 direct technical
 support
Albania
Azerbaijan
Croatia
Georgia
Egypt
Iran
Kenya
Senegal
Uganda
Number of national
 people trained
 through direct
 technical support
52 28 11
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